

Index

A

Abi3bp, 173
ABT-263, 205
Acinetobacter baumannii, 258, 260
ACTA2, 159
Actin cytoskeleton. *See* Cytoskeleton
Actin-depolymerization factor (ADF), 20
Adam10, 131
ADE. *See* Actin-depolymerization factor
Adipose stem cell (ASC), 395
Adrenergic receptor, 331
Adseverin, 20
Advillin, 20
African spiny mouse. *See* Wound-induced hair neogenesis
Aging
 chronic wounds and mesenchymal stem
 cell-derived extracellular vesicle reversal, 408
 senescence, 98–99
AGR2, 326
AGR3, 326
AHR, 262
AIF, 407
Aim2, 289
AIM-2, 360
Akt, 56–57, 231
AKT, 82, 274, 407–408
AKT-3, 345
Alloderm, 451
 $\alpha\beta$ T cell, immune niche in skin regeneration, 287
 α_2 -PI_{1–8}, delivery of growth factors and cytokines, 428–429
 α -SMA, 29, 31, 33, 176, 186–187, 189, 199, 201, 231, 248, 310,
 313, 383, 386–387
AME, 394
Amiloride, 48
Anaerococcus, 258, 262
Ang1, 242
Angiogenesis
 actin cytoskeleton remodeling, 27, 29
 chronic wound healing impairment, 365–367
 diabetic wounds, 245–246
 inflammation role in zebrafish, 10–11
 long noncoding RNA in wound healing, 81–82
 mesenchymal stem cell-derived
 extracellular vesicle promotion,
 406–407
 miRNA in wound healing, 73–74, 77, 245
 overview, 239–240
 pattern in healing wounds, 240
 regulation in healing wounds
 capillary pruning and maturation, 241–244
 proangiogenic phase, 240–241
 scarring, 246–248
 types in wounds, 244–245
Antimicrobial peptides. *See* *specific peptides*
Anxa2, 119

AP1, 132, 176
AP2 γ , 118
apoEC. *See* Apoptotic endothelial cell
Apoptosis, actin cytoskeleton remodeling, 31
Apoptotic endothelial cell (apoEC), 248
Apremilast, 465
Aquaporin, 45–46
Arg1, 289, 451
ARG1, 441
Arginase-1, 389
ARNT, 241
Arp2/3, 20, 22, 25, 27, 32
Arp1b, 116
ASC. *See* Adipose stem cell
ASPN, 162
AT1R, 204
AT2R, 204
ATM, 94, 96
Atorvastatin, 406
ATP2C1, 410

B

Basal cell carcinoma (BCC), 275
BCC. *See* Basal cell carcinoma
BCL-2, 101, 205
B cell, immune niche dynamics during wound repair, 287–288,
 291
Becaplermin, 418
Benzamil, 48
 β -Catenin, 155, 272, 278, 292, 357, 359, 394
Bilayered living cellular construct (BLCC), human skin
 equivalent, 368–369
Bioelectric signaling
 collective galvanotaxis mechanisms, 56–57
 electric fields at wounds, 46–48
 epidermal barrier, 44–45
 epithelial cell sheet migration guidance, 49, 51–56
 ion pumps in epidermis, 45–46
 keratinocyte migration guidance, 48–49
 overview, 41–44
 prospects for study, 58
 therapeutic applications, 57–58
Blimp1, 149, 188, 274
Blk1, 311
BMP. *See* Bone morphogenetic protein
BMPRIA, 277
Bone morphogenetic protein (BMP), 156
 Bmp4, 277
 Bmp7, 277
BRD4, 97, 102

C

C7, 465, 469
c-ABL, 204

Index

- CACNA1G, 390
CACNA1G-AS1, 390
Cadherin-2, 178
Cadherin-11, 201–202
Calcium flux, damage signaling in flies, 1–3
Cald1, 132
CapG, 20, 22
CapZ, 20
Cardiac fibrosis, 380
CARP, 241
Caspase-1, 289
Casr, 134
Caveolin1, 23
CB1r, 205
CB2r, 205
CBD. *See* Collagen-binding domain
CCG-1423, 202
CCL13, 229
Ccl2, 116
CCL2, 159, 230–231, 314, 316, 440
CCL3, 229
CCL5, 229
Ccl7, 116
CCL7, 229
CCL8, 229
CCL17, 291
CCL20, 290
CCL22, 291, 444, 449
Ccn1, 99
Ccn2, 99
CCN2, 204
CCNA2, 349
CCNB1, 349
CCNC, 344
CCNE1, 344
CCR2, 98, 227–228
CCR4, 291
CD19, 291
Cd26, 151, 160, 170, 172–173, 175, 188, 292
CD31, 138, 187, 452
CD34, 118
CD34, 285
CD35, 160
CD36, 175, 188
CD39, 160, 175
Cd44, 119
CD44, 449
CD45, 187
CD47, 176
CD62L, 227
CD68, 187
CD90, 160, 172, 188
Cd146, 153
CD163, 449
CD206, 233, 452
CD301b, 231
Cdc42, 4–5, 22–24, 26–28
CDK4, 94
CDK6, 81, 94
CEACAM6, 349
C/EBP, 97, 277
Celecoxib, 276
Cellular senescence. *See* Senescence
Cfl1, 116
CGRP, 330
Chronic wound healing. *See also specific wounds*
angiogenesis impairment, 365–367
economic impact, 401
extracellular matrix component imbalance, 367–368
fibroblast dysfunction, 364–366
inflammation, 360–364
keratinocyte dysfunction, 356–360
mesenchymal stem cell–derived extracellular vesicle
chronic wound healing treatment mechanisms
of action
aging reversal, 408–409
angiogenesis promotion, 406–407
antioxidant actions, 407–408
inflammation resolution, 403–406
intrinsic defect correction, 409–410
microRNA role, 79
myofibroblast mechanical stimulation therapy, 202–203
omics approaches to study, 356
oral mucosa healing comparative transcriptomics, 347–349
overview of ulcers, 355–356
prospects for study, 368–369
senescence, 100–102
Circular RNA
overview of noncoding RNA, 65–66
wound healing
role, 79–81
therapeutic targeting, 84
c-Jun, 176, 177
Ck1a, 4
Claudin-1, 45
Col1A1, 82, 186, 390
COL1A2, 156
COL1A2-AS1, 83
COL3A1, 390
Col6a1, 292
COL6A5, 159
COL7A1, 463–464, 466–469
COL11A1, 162
Col15a1, 188
Col17a1, 118
COL17A1, 463–464, 466, 469
COL17A1, 308
COL18A1, 159
COLA1, 364
Collagen-binding domain (CBD), protein engineering for
delivery of growth factors and cytokines, 428
Collagen scaffold, skin regeneration promotion, 443–445
Connexin43, 178
Corin, 173
Corynebacterium, 258
Corynebacterium striatum, 262
COX-1, 276
COX2, 134–135
COX-2, 276
Crabp1, 173, 311
CRISPR/Cas9, 84, 87–88, 466, 468, 473
Csf1r, 226
CSF3, 347
CTGF, 368, 391
Cutibacterium acnes, 258, 262
CX₃CL1, 274
CXCL1, 347
Cxcl2, 116
CXCL2, 347
CXCL8, 347
CXCL8, 9, 241, 362
CXCL10, 242, 246

- CXCL11, 242, 426
CXCL12, 423
CXCL13, 290
Cxcl14, 118
CX₃CR1, 227, 274
CXCR2, 98, 101, 289
CXCR3, 242, 246
Cyclin A2, 357
Cyclin B1, 357
Cyclin D2, 357
Cyclin E, 357
Cyclin M4, 357
Cytokine delivery systems. *See specific delivery systems*
Cytoskeleton
 myofibroblast mechanosignaling, 193–198
 remodeling in wound healing
 actin-binding proteins, 20–22
 apoptosis, 31
 filament types, 20
 hemostasis and inflammation role, 23–26
 overview, 19
 proliferative phase
 angiogenesis, 27, 29
 cell adhesion and spreading, 26
 granulation tissue formation and reepithelialization, 26
 migration of fibroblasts and keratinocytes, 27–28
 proliferation, 26–27
 prospects for study, 33
 Rho GTPases, 22–23
 scar formation, 30–31
 therapeutic targeting, 31–33
 tissue remodeling, 29–31
- D**
DAPI, 95
DBP. *See* Vitamin D-binding protein
dCELL, 451
Dcn, 152
DCN, 156
DDIT4L, 82
DDR. *See* Discoidin domain receptor
Decellularized extracellular matrix
 delivery of growth factors and cytokines, 419, 421
 skin regeneration promotion, 451
DECMA-1, 57
Deer, antler regeneration, 306–307
DEFB4A, 360
DEFB4B, 360
Defensin, 360
Delta, 244
Dendritic epidermal T cell (DETC), 111, 287, 289
Desmoglein 3, 410
Desmoplakin, 410
DETC. *See* Dendritic epidermal T cell
DFU. *See* Diabetic foot ulcer
DGC. *See* Dystrophin–glycoprotein complex
DGCR8, 66
Diabetic foot ulcer (DFU), 79–80, 256–257, 259, 262, 349, 355–356, 358–364, 366
Diacerin, 465
Dicer, 66–67
Digit tip regeneration. *See* Innervation; Regeneration
Diphtheria toxin, 327
Discoidin domain receptor (DDR), 178, 201–202
 DDR1, 193, 444
 DDR2, 193, 444
Dkk1, 272
Dlk1, 149, 170, 173, 188, 274
DLK1, 292
DLX1, 268
Double-stranded RNA (dsRNA), 294
Dpp4, 173, 175
DPP4, 159–160, 170, 172
Draper, 2
Drosha, 66–67
Drosophila
 actin assembly live imaging during wound epithelialization, 3–4
 damage signals, 1–3
 fat cells in wound healing, 6
 genetic analysis of wound pathways, 5–6
 hemocyte recruitment, 4–5
 immune cell extravasation, 6–7
 prospects for wound healing studies, 7
dsRNA. *See* Double-stranded RNA
DST, 463
Dual oxidase (DUOX), 2, 5, 9
DUOX. *See* Dual oxidase
Dystonin, 463
Dystrophin–glycoprotein complex (DGC), 23
- E**
E2F, 94–95
EB. *See* Epidermolysis bullosa
Ebf2, 188
EC-EKC, 10
EDAR, 276
Eef1b2, 118
EGF. *See* Epidermal growth factor
EGFR, 291, 359
EGFR, 349
Egr1, 133
Electric field. *See* Bioelectric signaling
EMP. *See* Endothelial–mesenchymal plasticity
EMP1, 77
ENaC, 45–46, 49
EndMT. *See* Endothelial–mesenchymal transition
Endothelial–mesenchymal plasticity (EMP)
 epithelial-to-mesenchymal transition comparison, 126–128, 135–136
 overview, 126–127
 pathological wound healing and therapeutic implications, 136–137
 prospects for study, 139
 wound healing mechanisms, 137–139
Endothelial–mesenchymal transition (EndMT), 138–139
Endothelial nitric oxide synthase (eNOS), 453
Endothelial progenitor cell (EPC), 367, 404, 408–409
Engrailed-1, 151–152, 155, 170, 173, 178, 188, 202
eNOS. *See* Endothelial nitric oxide synthase
Enterobacter, 258
EPC. *See* Endothelial progenitor cell
Eph, 389
Epidermal growth factor (EGF), 128, 244, 304, 406, 418–419, 422–423, 425, 428, 430, 449
Epidermal stem cell–immune niche
 dynamics during wound repair
 immune signal regulation of wound healing, 289–291

Index

- Epidermal stem cell-immune niche (*Continued*)
stem cell behavior, 288–289
tissue and cellular levels, 287–288
immune-related signals in skin regeneration
double-stranded RNA/TLR3/retinoic acid axis, 294
mechanical cue-immune axis, 295–296
microbiome, 294–295
neuro-immune-regeneration axis, 295
neutrophil extracellular trap impairment, 295
PGD2, 294
overview of immune niche, 287
- Epidermolysis bullosa (EB)
clinical features, 461–463
epidermal replacement
ex vivo cell and gene therapy combination, 468–470
holoclone-forming keratinocytes
generation, 470–471
molecular characterization, 471–473
overview, 467–468
revertant mosaicism, 468
genetics, 410, 461
genotype-phenotype correlation, 464
treatment
drugs, 465–467
gene therapy, 467
prospects, 473
protein and cell therapies, 466–467
tailored therapies, 465
types
dystrophic epidermolysis bullosa, 463–464
epidermolysis bullosa simplex, 463
junctional epidermolysis bullosa, 463
Kindler epidermolysis bullosa, 463
wound healing, 464–465
- Epiplakin, 410
- Epithelial-to-mesenchymal transition (EMT)
endothelial-mesenchymal plasticity comparison, 126–128, 135–136
molecular signatures, 116
overview, 126–127
reepithelialization
parallels, 132–135
suppression, 135–136
- ERK, 10–11, 26, 314, 408
- Erk5, 133
- Escherichia coli*, 258
- ETS2, 118
- EudraCT, 465
- EV. *See* Extracellular vesicle
- EXPH5*, 464
- Exportin 5, 66
- Extracellular vesicle (EV)
bioactive materials, 402–403
functional overview, 403
mesenchymal stem cell. *See* Mesenchymal stem cell-derived extracellular vesicles
miRNAs in wound healing, 78–79
- EZH2, 82
- F**
- F1, 152
F2, 152
F3, 152
F4, 152
Fabp4, 311
- FAK. *See* Focal adhesion kinase
- FAP. *See* Fibroblast activation protein
- FASCIN-1, 134
- Fat body cell, wound healing role in flies, 6, 12
- FBR. *See* Foreign body response
- Fc, therapeutic protein stabilization, 430
- FcR, 25
- FcεRI, 387
- FERMT1*, 463
- FGF. *See* Fibroblast growth factor
- Fibrin hydrogel, skin regeneration promotion, 445–446
- Fibroblast. *See also* Myofibroblast
actin cytoskeleton in migration, 27–28
anatomic location and heterogeneity, 173–174
chronic wound healing dysfunction, 364–366
epidermolysis bullosa cell therapy, 467
functional overview, 149
heterogeneity in humans
healthy skin
developmental programs, 160–161
functions, 160
markers and subpopulations, 156–160
regulatory mechanisms, 161
spatial localization, 160
prospects for study, 163
wound healing
functions, 161
pathology, 161
heterogeneity in mouse
healthy skin
adults, 152
developmental changes, 149–152, 170–172
pericyte origins, 152–153
wound healing
dermal-epidermal communication, 155
embryo studies, 153
microenvironment effects, 155–156
populations in wound bed, 153–155
human versus mouse, 147–149, 162–163
keloid role, 384, 386
miRNA in wound healing, 75–78
origins and functions in skin, 170–173
skin layer and heterogeneity, 174–176
wound repair and scar formation roles
immunosignaling, 179
mechanosignaling, 178–179
migration and extracellular matrix mobilization, 176, 178
phenoconversion and extracellular matrix deposition, 176
wound-induced hair neogenesis role, 274–275
- Fibroblast activation protein (FAP), 82, 175, 188
- Fibroblast growth factor (FGF), 8, 11
FGF-1, 429–430
FGF-2, 29, 77, 138, 203, 241, 291, 418–419, 425–430
FGF-7, 386, 428
Fgfβ, 442
FGF-9, 272, 275–276, 295, 311, 442
FGF-10, 386
FGF-18, 179
FGF-22, 386
FGFR2, 272
FGFR3, 272
- Fibronectin, 131, 383, 426
- Fibrotic disease. *See specific diseases*
- Filamin, 32
- Finegoldia*, 258, 262

- Flg, 285
Flightless I (Flii), 20, 22, 27, 32–33
Flii. *See* Flightless I
FLT1, 241
Fluorouracil, 392
FMO, 159
FN1, 368
FNB1, 80
Focal adhesion kinase (FAK), 23, 179, 195,
307, 314, 318
Foot ulcer. *See* Diabetic foot ulcer
Foreign body response (FBR), 11
Fos, 116, 133
FOXF1, 390
FOXM1, 349, 362, 410, 472
FOXP3, 388
Fscn1, 132
FSP1, 137–138
- G**
GADD45, 6
Galectin-3, 49
Galvanotaxis. *See* Bioelectric signaling
 $\gamma\delta$ T cell
immune niche in skin regeneration, 287, 295
wound-induced hair neogenesis role, 272, 274,
441–442
Gas5, 357
GAS5, 81, 84
GATA2, 77
Gata6, 288
Gelsolin, 20–22, 31–33
Gentamicin, 466
Gli1, 275–276
Gli2, 275
Gli3, 275
Glut1, 134
GM-CSF, 418–419
Gold nanoparticles, delivery of growth factors and cytokines,
423
gp130, 391
Gpr44, 442
Gpr44, 294
GPR44, 276–278
GPR84, 7
Gpx3, 152
GPX3, 175
Grem2, 173
Grhl2, 128
Grhl3, 134
Growth factor delivery systems. *See specific delivery systems*
GSK3 β , 272
- H**
H19, 81–82, 84
Hair follicle (HF)
bulge signature, 118, 128
cellular heterogeneity, 112–113
stem cell adaptation in wound healing, 119–121
stem cell markers, 269–271
transient lineage infidelity, 118–119
wound experience cell memory, 119
wound reepithelialization, 114–115
wound-induced neogenesis. *See* Wound-induced hair
neogenesis
HBB, 344
HBD. *See* Heparin-binding domain
HB-EGF, 246, 347
HBEGF, 77
Hedgehog, 155, 275, 278
Hemocyte, recruitment to wound, 4–5
Heparin, biomaterial functionalization for
delivery of growth factors and cytokines, 425–426
Heparin-binding domain (HBD), protein engineering for
delivery of growth factors and cytokines, 428
Hepatocyte growth factor (HGF), 128
HF. *See* Hair follicle
HGF. *See* Hepatocyte growth factor
Hic1, 173, 188
HIF. *See* Hypoxia-inducible factor
Hippo, 310, 314
Histamine, 360
HLA-E, 99
HMGB1B1, 96
HOTAIR, 82, 84
HOXA11-AS, 83
HOXA11-AS, 390
HPI, 344
Hyaluronic acid hydrogel, skin regeneration promotion,
446, 449, 452
Hydrogel
delivery of growth factors and cytokines, 419, 421–422
heparin functionalization, 425–427
MAP hydrogel, 450–451
skin regeneration promotion
fibrin hydrogel, 445–446
hyaluronic acid hydrogel, 446, 449, 452
Hydrogen peroxide, 304, 407
Hydrogen peroxide, wound healing signaling, 2, 5, 7, 9
Hypoxia-inducible factor (HIF), 9
HIF1a, 139
HIF1A, 82
HIF-1 α , 82, 232, 241, 290, 307, 387, 409
HIF-1 β , 241
- I**
ICAM-1, 25, 230
ICAM-2, 230
Id3, 227
IFE. *See* Interfollicular epidermis
Ifitm3, 118
IFN. *See* Interferon
IgE, 387–388
IGF-1, 241, 289, 363, 388–389, 428, 430
IGF2BP2, 77
IL. *See* Interleukin
ILC. *See* Innate lymphoid cell
Inducible nitric oxide synthase (iNOS), 446, 449, 452
INK4A, 94
Innate lymphoid cell (ILC), 290
Innervation
bone repair role of Schwann cells, 331–332
digit tip regeneration role in mammals
overview, 326–327, 329
Schwann cell trophic support for blastema expansion,
327–328
mesenchymal cells in digit tip regeneration and skin repair,
332–333

Index

- Innervation (*Continued*)
 nerve anatomy, 324
 nerve-dependent regeneration and Schwann cell function, 325–326
 peripheral nervous system overview, 323–325
 prospects for study in tissue repair and regeneration, 333–334
 wound healing role, 328, 330–331
- iNOS. *See* Inducible nitric oxide synthase
- Interferon (IFN)
 IFN- β , 231, 441
 IFN- γ , 287, 290, 359
- Interfollicular epidermis (IFE)
 basal signature, 118
 cell states at wound repair time points, 118
 cell types and structure, 111–113, 285–288
 stem cell markers, 269–271
 transient lineage infidelity, 118–119
 wound experience cell memory, 119
 wound reepithelialization, 114–115
- Interleukin (IL)
 IL-1, 186, 230, 289, 387, 408, 453
 IL-1 β , 10, 12, 344, 362, 442, 465
 IL-1R, 295
 IL-2, 363
 IL-4, 205, 228, 231–232, 287, 289, 388, 402, 425, 441, 451
 IL-4R, 179
 IL4R α , 289
 IL6, 349
 IL-6, 67, 79, 230, 278, 289–291, 294, 344, 362, 390, 395, 404, 440, 442, 449
 IL-6R, 391
 IL-8, 67, 290, 360
 IL-10, 232, 289–291, 308, 388, 402, 404, 419, 425, 441, 444, 449, 452–453
 IL-11, 205
 IL-12, 230, 404, 440–441, 449
 IL-13, 205, 228, 232, 287, 289, 388, 441, 451
 IL-13R, 179
 IL-15, 344–345
 IL-17, 139, 277, 295
 IL-22, 430
 IL-23, 295
 IL-25, 289
 IL-33, 289
- Inv, 285
- ISCU, 77, 79
- Itga3*, 119
- ITGA3*, 463
- Itga5*, 116
- ITGA6*, 463
- Itgb1*, 116, 119
- ITGB4*, 463–464
- J**
- JAK, 391
- JAM-A, 230
- JAM-B, 230
- Jun*, 133
- K**
- K1, 285, 357
- K5, 268, 276, 463
- K6, 132
- K10, 269, 285, 357
- K14, 268, 271, 274, 275, 277, 311, 347, 463
- K15, 269, 271, 285, 288, 292
- K16, 132
- K17, 132
- KASH, 198
- 30Kc19 α , therapeutic protein stabilization, 429
- KDR, 241
- Keloid
 cell alterations and gene expression profiling
 fibroblast, 384, 386
 keratinocyte, 387
 macrophage, 388–389
 mast cell, 387–388
 myofibroblast, 386–387
 regulatory T cell, 388
 single-cell analysis, 389
 cell signaling and immunomodulatory pathways, 385
 connective tissue composition and collagen accumulation, 382–383
 fibroblast heterogeneity, 161–162
 fibrotic skin disorder overview, 380–382
 genetics, 384
 immune dysregulation and cytokine modulation of gene expression
 IL-6-mediated JAK/STAT signaling, 391
 NF- κ B signaling, 391–392
 overview, 390
 TGF- β /Smad signaling, 390–391
 microneedle delivery of growth factors and cytokines, 424–425
 noncoding RNA role, 389–390
 treatment, 392–394
- Keratin. *See specific keratins*
- Keratinocyte
 actin cytoskeleton in migration, 27–28
 chronic wound healing dysfunction, 356–360
 electric fields and migration guidance, 42, 48–49
 holoclone-forming keratinocytes for epidermolysis bullosa management
 generation, 470–471
 molecular characterization, 471–473
 keloid role, 387
 reepithelialization adhesion and cytoskeletal changes, 130–132
 sealing of wound in zebrafish, 8
- Keratinocyte growth factor (KGF), 387, 402, 428–429
- KGF. *See* Keratinocyte growth factor
- Kidney fibrosis, 380
- Kir4.2, 49
- KIT, 359
- Klebsiella pneumoniae*, 258
- KLF4*, 346
- KLF5*, 118
- KLK12*, 349
- KRAS, 359
- Krt2a*, 349
- KRT5*, 463–464
- KRT6, 345
- Krt6a*, 119
- KRT14*, 272, 463–464
- KRT17, 345
- L**
- LAIR-1, 444
- LAMA3, 463

LAMB3, 463, 466, 468–469
LAMC2, 463
Lamin, 198
Lamin B1, 96
Laminin, 426, 463
Laminin-1, 131
Langerhans cell (LC), 32, 111
LAP. *See* Latency-associated peptide
Laser ablation, keloid, 392
Latency-associated peptide (LAP), 195
Lats1, 472
Lats2, 472
LCN2, 344
Ldha, 116
Lef1, 174
LEF1, 276, 272
LEM, 198
LEMD3, 381
LEMD3, 381
Lenabasum, 205
Leukotriene B₄ (LTB₄), 9
LFA-1, 227
Lgr5, 118, 119–121
Lgr5, 285, 288, 292
Lgr6, 269
Lgr6, 121, 285, 288, 292
LINC00312, 390
LINC complex, 198, 314
Lipopolysaccharide (LPS), 228, 230, 232–233, 287, 404–405, 430, 448
Liposome, delivery of growth factors and cytokines, 422–423
Lirb4a, 344
Liver fibrosis, 380
LL-37, 402, 405
lncRNA. *See* Long noncoding RNA
Long noncoding RNA (lncRNA)
keloid role, 390
overview of noncoding RNA, 65–66, 81
wound healing role
angiogenesis, 81–82
biomarker utilization, 85
granulation tissue formation, 82
inflammation, 81
reepithelialization, 81
scar formation, 82–83
therapeutic targeting, 84
Loricrin, 269
Losartan, 204, 395, 465
LOX. *See* Lysyl oxidase
LOXL2, 200
LPA1, 201
LPS. *See* Lipopolysaccharide
Lrc, 285
Lrig, 285
Lrig1, 149, 153, 170, 188, 274, 288–289
Lrig6, 288
LRP6, 245
LRRC15, 186
LSP1, 159
LTB₄, 9
LTBP-1, 186, 195
LUM, 156
Ly6a, 175
Ly6e, 118
Lyn, 9
Lysyl oxidase (LOX), 192, 200–201

M

Mac-1, 230
Macrophage
activation
early wound phase, 229–230
late wound phase, 231–232
metabolism determination of activation, 232–233
mid-wound phase, 230–231
overview, 228–229
chronic wound healing, 363
fate, 233
immune niche dynamics during wound repair, 287–288, 293–294
keloid role, 388–389
mesenchymal stem cell–derived extracellular vesicle effects, 404, 408
oral mucosa, 342
origins
development, 225–227
effect on wound healing function, 228
overview of wound repair response, 223–224, 440–441
recruitment live imaging in zebrafish, 9–10
therapeutic targeting, 233–234
wound-induced hair neogenesis role, 274
MALAT1, 82
MALAT1, 407
MAP hydrogel, 450–451
Mast cell
immune niche dynamics during wound repair, 290
keloid role, 387–388
Matrix metalloproteinase (MMP)
MMP1, 349, 464
MMP1, 367
Mmp1b, 116
MMP2, 289
Mmp9, 116
MMP9, 81
MMP9, 12, 289, 367, 386
Mmp13, 116
MMP13, 367
mbGR, 357, 359
MCAM, 230
MCP-1, 314
MDM2, 94
Mechanosignaling
epidermal stem cell mechanical cue–immune axis, 295–296
fibroblast, 178–179
myofibroblast
cytoskeletal mechanosignaling, 193–198
mechanical memory, 198–200
mechanical stimulation therapy for chronic wound healing, 202–203
wound stiffness, 192–193
regeneration tissue mechanics
immune signaling and transcriptional changes, 316
mechanochemical transduction, 314–315
repair response activation, 314, 316
wound healing, 313–314
wound-induced hair neogenesis mechanochemical events, 309, 311, 313
Mesenchymal-to-epithelial transition (MET)
endothelial–mesenchymal plasticity comparison, 126–128
overview, 127

Index

- Mesenchymal stem cell (MSC)
functional overview, 402
markers, 402
therapeutic applications, 402
wound healing mechanisms, 402
- Mesenchymal stem cell–derived extracellular vesicles
chronic wound healing treatment mechanisms of action
aging reversal, 408–409
angiogenesis promotion, 406–407
antioxidant actions, 407–408
inflammation resolution, 403–406
intrinsic defect correction, 409–410
clinical application, 410–411
delivery, 410
rationale for therapy, 403
- Mest, 311
- MET. *See* Mesenchymal-to-epithelial transition
- Methicillin-resistant *Staphylococcus aureus* (MRSA), 260
- MFAP5, 160
- Microbiome. *See* Wound microbiome
- Microneedle, delivery of growth factors and cytokines, 424–425
- MicroRNA (miRNA)
biogenesis, 66
functional overview, 66
keloid role, 389–390
mesenchymal stem cell–derived extracellular vesicles, 405–406
oral mucosa wound healing, 345
overview of noncoding RNA, 65–66
wound healing role
angiogenesis, 73–74, 77
chronic wound healing, 79
extracellular vesicle miRNAs, 78
fibroblast function, 75–78
inflammatory response, 67–70, 77
overview, 66–67
pleiotropic miRNAs in wound repair, 78
reepithelialization, 71–72, 77
therapeutic targeting, 83–84
- Microsphere, delivery of growth factors and cytokines, 423
- Migratory leading edge, wound healing, 116–118
- miRNA. *See* MicroRNA
- MKL-1, 197
- MLCK, 24, 29, 189, 192
- MMP. *See* Matrix metalloproteinase
- MRSA. *See* Methicillin-resistant *Staphylococcus aureus*
- MRTF-A, 197, 199–200, 202–203
- MSC. *See* Mesenchymal stem cell
- Mst1, 472
- Mst2, 472
- MSX1, 175
- Mth110, 2
- mTORC1, 231
- Mts24, 285
- Myb, 226–227
- MYC, 346
- MyD88, 261
- Myh9, 132
- Myo1b, 132
- Myofibroblast
contraction and function
granulation tissue, 189
lockstep model, 189–192
definition, 185–187
immune niche dynamics during wound repair, 287
keloid role, 386–387
mechanosignaling
cytoskeletal mechanosignaling, 193–198
mechanical memory, 198–200
mechanical stimulation therapy for chronic wound healing
healing, 202–203
wound stiffness, 192–193
origins, 187–189
prospects for study, 206
scarring role, 183–185
therapeutic targeting
inhibition of mechanotransduction and contractile pathways, 200–202
mechanical stimulation for chronic wound healing, 202–203
molecular targets, 203–206
- Myosin II, 26, 313, 318
- ## N
- NADPH oxidase (NOX), 2, 367
- nAG, 326
- NANOG, 408–409
- Nanoparticles, delivery of growth factors and cytokines, 423
- Natural killer cell
chronic wound healing, 363
immune niche dynamics during wound repair, 287, 290
- Nav2, 132
- NDD4, 383
- Ndufa4*, 116
- Ndufa4l2*, 129–130
- Negative-pressure wound therapy (NPWT), 203
- Nestin, 153
- NET. *See* Neutrophil extracellular trap
- Neurotensin (NT), 328
- Neutrophil
chronic wound healing, 362–363
immune niche dynamics during wound repair, 287
recruitment live imaging in zebrafish, 9–10
- Neutrophil extracellular trap (NET), 9, 25, 295, 362
- Nfib*, 119
- NF- κ B. *See* Nuclear factor κ B
- Ng2, 153, 170
- NHE1, 45
- Nilotinib, 204
- Nitric oxide (NO), 230, 289
- NK2GA, 99
- NKG2D, 97
- NMBR*, 344
- NO. *See* Nitric oxide
- Noncoding RNA. *See* Circular RNA; MicroRNA; Long noncoding RNA
- NOS1A β , 367
- Notch, 244
- Notch1, 366
- NOTCH1*, 465
- Notum*, 173
- NOX. *See* NADPH oxidase
- NPWT. *See* Negative-pressure wound therapy
- NPY, 330
- NPY-2Ra, 328
- Nrf2, 6, 99
- NRF2, 407–408
- NRP1, 241
- NRP2, 241

NS-398, 135
Nuclear factor κ B (NF- κ B), 23, 97, 101–102, 290, 390–391

O

Occludin, 44
OCT4, 346
OCT4, 408–409
Oleogel-S10, 465
Oral mucosa
 epithelial layers, 340–341
 immune cells, 341–342
 mouse models of wound healing, 347
 regeneration studies, 307
 transcriptomics of wound healing capacity
 chronic wound healing comparison,
 347–349
 cutaneous wound healing comparison,
 342–347
 overview, 342
OSM, 328–331
Osterix, 332
Ouabain, 48
Ovol1, 136
Ovol1, 128
Ovol2, 135–136
Ovol2, 128, 135

P

P-2, 360
p16, 94, 96–98, 100
p21, 94, 97, 100, 128
p53, 94, 100, 128
P53, 359
p63, 471
p107, 357
p110 γ , 57
p130, 357
PAI-1, 100, 364, 391, 394
PARP1, 407
PAX9, 346
PCA3, 85
PCP. *See* Planar cell polarity
PDCD4, 199
PDGF, 77, 203–204, 206, 229–231, 242, 246, 289, 291, 342,
 387–389, 441
PDGF-AA, 99, 328–331
PDGF-BB, 366, 418–419, 426–428, 430–431
Pdgfra, 149, 153
PDGFR α , 156, 170, 187, 326, 330
Pdgfr β , 153
PDGFR β , 242
PDL1, 359
PECAM-1, 24, 138
PEDE, 242, 245–246
PEG. *See* Polyethylene glycol
PEGDA. *See* Polyethylene glycol diacrylate
Peptococcus, 258
Peptoniphilis, 258
Perforin-2, 260
Pericyte, fibroblast origins, 152–153
Peripheral nervous system. *See* Innervation
PG. *See* Prostaglandin
Piezo1, 192
PIEZO1, 134

PIGF-2, 426, 428
Pil6, 188
Pil6, 175
PITX1, 346
PITX1, 307
PITX2, 346
PKC, 357
PKC α , 131
Pkm, 116
Plac8, 175
Planar cell polarity (PCP), 134
Plaur, 116
PLEC, 463–464
Plectin, 410, 463
PLGA. *See* Poly(lactic co-glycolic acid)
Plod1, 82
Pluronic F127, delivery of growth factors and cytokines, 422
Podoplanin, 188
Poly(lactic co-glycolic acid) (PLGA)
 delivery of growth factors and cytokines, 422–423
 skin regeneration promotion, 449
Polyethylene glycol (PEG)
 delivery of growth factors and cytokines, 422, 426
 PEGylation of therapeutic proteins, 429
 skin regeneration promotion, 449–450
 starPEG hydrogels, 425
Polyethylene glycol diacrylate (PEGDA), 450
Porphyromonas, 258
POSTN, 162
PPAR- γ , 188, 291
Pressure ulcer (PU), 258, 262, 355–356, 358–359, 361–362,
 364–365
Prevotella, 258
P-Rex-1, 27
Procr, 116
Proliferative zone, wound healing, 116–118
Prostaglandin (PG)
 PGD2, 276, 278, 294, 442
 PGE2, 10, 134, 276, 294
 PGF_{2 α} , 276
Proteus, 258
Prrx1, 151–152, 173–174
Prss35, 311
Pseudomonas aeruginosa, 258, 260
Psoriasis, 360
Ptch, 275
PTEN, 67, 77, 82
PTEN, 83, 406
PTGDR, 276
Ptgds, 277
PTGDS, 294
PU. *See* Pressure ulcer
PU.1, 224
Pulmonary fibrosis, 380
PWD3, 278
PWD7, 278

R

Rab18, 453
Rac, 4–5, 22–24, 26–27
Rac1, 130, 134
RAC1, 268, 272
RAD50, 359
RAN-GTP, 66

Index

- RASA1*, 77
Rb, 357
RBPJ, 138
Rbpj, 139
Reepithelialization
 epidermal cellular activity spatial patterning, 128–130
 epithelial-to-mesenchymal transition
 parallels, 132–135
 suppression, 135–136
 hair follicle role, 114–115
 interfollicular epidermis, 114–115
 keratinocyte adhesion and cytoskeletal changes, 130–132
 long noncoding RNA role, 81
 microRNA role, 71–72, 77
 overview, 128
Regeneration. *See also* Wound-induced hair neogenesis
 animal models
 age effects, 317
 overview, 316–317
 skin anatomy, 317–318
 tissue mechanics, 318
 biomaterial-induced regeneration, 450–451
 examples
 determining factors between species, 284–285, 305
 lizard, 306
 mammals
 deer antler, 306–307
 digit regeneration, 306
 ear punch, 307
 human potential, 307–308
 oral mucosa, 307
 Planaria, 304
 zebrafish, 304
 immune-related signals in skin
 double-stranded RNA/TLR3/retinoic acid axis, 294
 mechanical cue–immune axis, 295–296
 microbiome, 294–295
 neuro-immune-regeneration axis, 295
 neutrophil extracellular trap impairment, 295
 PGD2, 294
 innervation role. *See* Innervation
 overview, 303–304
 prospects for study, 296
 salivary gland, 342
 scaffolds for skin regeneration promotion
 collagen scaffold, 443–445
 fibrin hydrogel, 445–446
 hyaluronic acid hydrogel, 446, 449
 synthetic biomaterials, 449
 tissue mechanics
 immune signaling and transcriptional
 changes, 316
 mechanochemical transduction, 314–315
 repair response activation, 314, 316
 wound healing, 313–314
Regranex, 418
Regulatory T cell (Treg)
 immune niche dynamics during wound repair, 290–291
 keloid role, 388
REL α , 289
Resveratrol, 204
Retinoic acid, 294
Revertant mosaicism, 468
Rgs5, 153
RGS5, 159
Rho, 4–5, 22–24, 26–27, 30–31
RHO, 344
RhoA, 189, 192, 201, 203, 206, 394
RhoB, 192
RhoC, 192
RIG-1, 346
RNA interference
 epidermolysis bullosa management, 467
 keloid management, 392, 394
RNase L, 288, 295
ROCK, 23, 26–27, 29–31, 172, 189, 201, 206
ROCK1, 192, 394
ROCK2, 192
Rok, 4
ROR γ , 290
RP11–91I11.1, 390
Runx1, 311
RUNX1, 82
Runx2, 394
Runx3, 227

S
S100A7, 360
S100A8, 360
S100A9, 360
Sad1p, 198
SAHF, 95–96
SASP. *See* Senescence
SBD. *See* Syndecan-binding domain
Sca1, 170, 175, 188, 311
Scarring
 angiogenesis impairment, 246–248
 economic impact, 169
 fibroblast heterogeneity, 161–162
 microneedle delivery of growth factors and cytokines, 424–425
 myofibroblast
 role, 183–185
 therapeutic targeting, 200–202
SCC. *See* Squamous cell carcinoma
SCD. *See* Sickle cell disease
Schwann cell
 bone repair role, 331–332
 development, 324–325
 digit tip regeneration role in mammals
 overview, 326–327, 329
 Schwann cell trophic support for blastema expansion,
 327–328
 functions, 324
 wound healing role, 328, 330–331
Scn7a, 45
Scrb1, 134
SDF-1, 423
SDHD, 79
SELEX, 427
SEMA3F, 9
Senescence
 aging, 98–99
 biomarkers, 95–96
 cellular pathways, 93–95
 chronic wound healing, 100–102
 embryogenesis, 97–98
 prospects for study, 102–103
 SASP, 94, 96–100
 wound healing role, 99–100
Senescence-associated β -galactosidase, 96
Setdb2, 231

- SFRP1, 188
SFRP2, 159, 188
SFRP4, 442
Shark, 2
Shh. *See* Sonic hedgehog
Sickle cell disease (SCD), 258
SIRT1, 80
Site-directed mutagenesis, therapeutic protein stabilization, 430
Skin regeneration. *See* Regeneration
SLCIA3, 268
Slug, 126, 132–133, 138
SMA, 138
Smad2, 390–391
SMAD2, 77
SMAD2, 405
Smad3, 390–391
Smad6, 391
Smad7, 83, 391
Smoothed, 275
Snai2, 116, 132, 136
Snail, 126, 138
SOD2, 349
Sonic hedgehog (Shh), 178, 275–276, 292, 310
Sox2, 327, 346
Sox2, 149, 203, 307, 330, 347
SOX2, 346–347
Sox9, 118–119
SOX9, 118, 139
SP. *See* Substance P
Sparc, 118
Sponge scaffold, delivery of growth factors and cytokines, 419, 421
Spp1, 119
SPP1, 368
Sprouty2, 246
SPRR1A, 357
SPRR1B, 357
SPRR2B, 357
SPRR3, 349
SPRR3, 357
SPRY1, 199
Squamous cell carcinoma (SCC), 346, 349, 461, 463–465
Src, 23
Src42a, 2
Ssc. *See* Systemic sclerosis
Staphylococcus aureus, 256–258, 260–262, 295, 360, 442
Staphylococcus epidermidis, 256, 258, 260–262, 295, 360
Staphylococcus lugdunensis, 261
STAT1, 81
STAT3, 349
STAT3, 276, 278, 289–290, 294, 362, 391, 408, 442
Streptococcus agalactiae, 257
Substance P (SP), 328
SUN, 198
Supervillin, 20
Surfactin A, 452
SYK, 25
Syndecan-binding domain (SBD), therapeutic protein signaling modulation, 430–431
Systemic fibrotic disease, 380
Systemic sclerosis (Ssc), 185, 201, 204–205
- T**
- TAF4, 290
Tagin, 173
TAZ, 179, 197, 199–200, 202, 206, 314
Tbx18, 153
T cell. *See* specific cells
T-cell receptor (TCR), 363
TCF3, 118
Tcf7l1, 119
TCR. *See* T-cell receptor
TEER. *See* Transepidermal electrical resistance
Tegaderm, 446
Tenascin, 368
Tenascin C, 131, 386
TEP. *See* Transepithelial potential
TETLA, 81
TEWL. *See* Transepidermal water loss
TGF- β . *See* Transforming growth factor β
Thbs1, 119
Thymosin b4, 32–33
TIE1, 138
Tie2, 242
TIE2, 138
Tim4, 290
TIMP, 291
TIMP1, 204, 289, 367, 394
Timp2, 116
TIMP2, 394
TIMP3, 77
TLR, 346
TLR. *See* Toll-like receptor
TLR3, 275–276, 278–288, 294, 310, 359, 442
TLR4, 291, 383, 392
Tnc, 119
TNFR1, 391
TNFR2, 391
TNF- α . *See* Tumor necrosis factor α
Toll-like receptor (TLR), 230
TP63, 346
Tpm1, 132
Tpm2, 116
Transepidermal electrical resistance (TEER), 44
Transepidermal water loss (TEWL), 44
Transepithelial potential (TEP), 46–47
Transforming growth factor β (TGF- β), 29–30, 77, 82, 98, 101, 128, 132, 137, 156, 172, 176, 191, 195, 201, 203, 205–206, 231, 241, 274–275, 289, 291, 293, 304–305, 314, 349, 364, 366, 368, 381, 383–384, 386, 388–391, 402, 405–406, 441, 449, 465
TGF- β 1, 426
TGF- β 3, 418–419, 425
TGFR β 1, 162
TGFB2, 77
Trel, 7
Treg. *See* Regulatory T cell
TREM1, 362
TRHDE-AS1, 83
Tip63, 118
TRPA1, 277, 295
TRPV3, 46
TRPV4, 45, 191, 202
Tryptase, 362
TSG-6, 405
TSLR, 289
TSP-1, 246, 465
TSP-2, 453
TTK, 344
Tubb2a, 132
Tubb3, 132

Index

- Tubb6, 132
Tumor necrosis factor α (TNF- α), 10, 12, 137,
230, 234, 274, 289, 293, 344, 349,
360, 362, 391, 404, 408, 440, 442,
444, 453
Turing patterning, wound-induced hair neogenesis, 310–312
Twist1, 126, 292, 310–311
TWIST1, 136
- V**
Vangl2, 134
Vascular endothelial growth factor (VEGF), 10, 29, 49, 291, 344,
386–387, 394, 402, 406, 430, 441, 444, 449, 453
 VEGF, 77
 VEGFA, 82
 VEGF-A, 231–232, 241, 244, 289, 418, 423, 426–431
 VEGF-B, 231
 VEGF-C, 429
 VEGFR1, 241
 VEGFR2, 77
 VEGFR2, 241, 431
VCAM-1, 25, 230
Vcan, 119
VEGF. *See* Vascular endothelial growth factor
Venous leg ulcer (VLU), 258, 349, 355–365, 368–369, 449
Villin, 20
VIM, 156
Vimentin, 116, 132, 134, 138
Vitamin D-binding protein (DBP), 25–26
VLA-4, 230
VLU. *See* Venous leg ulcer
von Willebrand factor, 138
- W**
WAKMAR1, 81
WAKMAR2, 81
WASP. *See* Wiskott–Aldrich syndrome protein
WEE1, 359
WIHN. *See* Wound-induced hair neogenesis
Wiskott–Aldrich syndrome protein (WASP), 20,
22, 24, 27
Wnt, 178, 272, 275, 394
WNT, 359
Wnt1, 174
Wnt7b, 276
wnt16, 12
Wound electric field. *See* Bioelectric signaling
Wound microbiome
 beneficial microbes, 261–262
 biofilms, 259–260, 262
 microbe types, 256–258
 overview, 253–254
 prospects for study, 262–263
 skin regeneration effects, 294
 survival, 259–260
 techniques for study, 254–256
Wound-induced hair neogenesis (WIHN)
 cell roles
 epithelial stem cells, 268–272, 292
 fibroblast, 274–275
 $\gamma\delta$ T cells, 272, 274
 macrophage, 274
 mechanochemical events, 309, 311, 313
 microbiome effects on wound healing, 261
 microenvironment, 277–278
 mouse
 African spiny mouse, 310, 331
 laboratory mouse, 308, 310
 overview, 267–268, 284, 291–292
 responses in different parts of wound bed, 311
 signaling pathways
 arachidonic acid metabolites, 276–277
 BMP-ZFP423 pathway, 277
 dermal signals, 292–294
 epidermal signals, 292
 Hedgehog, 275
 overview, 273, 275
 TLR3, 275–276
 skin regeneration model, 308
 species differences, 306
 therapeutic application, 277–279
 Turing patterning in wound bed, 310–312
- X**
XIST, 82
- Y**
Y-27632, 31
YAP. *See* Yes-associated protein
Yes-associated protein (YAP), 172, 179, 197, 199–200, 202, 206,
292–293, 310, 314, 316, 446, 469, 471–472
Yrk, 9
- Z**
Zeb1, 126, 128, 133, 135, 138
Zeb1, 136
ZEB1, 132
Zebrafish
 cutaneous nerve role in wound healing, 13
 fat body cell role in wound healing, 12–13
 heart, gill, and skeleton studies of wound healing, 11–12
 inflammation roles
 angiogenesis, 10–11
 scar collagen deposition, 11
 keratocyte sealing of wound, 8
 melanocyte role in wound healing, 12
 neutrophil and macrophage recruitment live imaging, 9–10
 overview of wound healing model, 7–8
ZFP423, 277
Zona occludens-1, 45